NCT02525796View on ClinicalTrials.gov

Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

October 1, 2021

Study Completion Date

October 2, 2021

Conditions
Primary Hyperparathyroidism
Interventions
DRUG

eplerenone

eplerenone, titrated up to a maximum of 50mg BID

DRUG

amiloride

amiloride, titrated up to a maximum of 10mg BID

DRUG

Placebo

DRUG

Cinacalcet

Cinacalcet, as add-on therapy in addition to eplerenone/amiloride/placebo, titrated up to a maximum of 30mg BID

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER

NCT02525796 - Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism | Biotech Hunter | Biotech Hunter